NuvaRing, manufactured by Organon USA, Inc., is a vaginal ring which contains the hormones estrogen and progestin. NuvaRing was approved by the FDA on October 3, 2001. Since its initial approval, NuvaRing has been linked to an increased risk of blood clots. If left untreated, blood clots can develop into more serious conditions including pulmonary embolism (blood clot in the lung), stroke, heart attack and deep vein thrombosis (DVT). The current label and package insert for NuvaRing do not warn of the potential serious health effects associated with its use as a vaginal hormonal contraceptive.
Symptoms and conditions that have been associated with the use of combination hormonal contraceptives, such as NuvaRing, include:
Suthers Law Firm is investigating cases in which individuals suffered serious injuries or wrongful death while using the NuvaRing vaginal contraceptive. If you or someone you know has experienced any of the symptoms listed above, contact us online or call us on our toll free number, 1-800-320-2384, to set up a FREE consultation.